What this is
- How it works
- How it works isn't classified yet
- Tested for
- Graves Disease (2 trials), Graves' Disease
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid”In the company’s words, NCT07661056 on ClinicalTrials.gov
Other drugs for Graves Disease
- IBI311Innovent · Phase 3
- MHB018AMinghui Pharmaceutical (Hangzhou) Ltd · Phase 3
- ZL-1109Zai Lab (Shanghai) Co., Ltd. · Phase 3
- KHN939Beijing Kanghong Biological Medicine Co., Ltd. · Phase 3
- LinsitinibSling Therapeutics, Inc. · Astellas · Phase 3
- Efgartigimodargenx · Phase 3
Coming up3
- Sep 2027Phase 1 trial completes · ClinicalTrials.gov
- Jan 2028Phase 3 trial completes · ClinicalTrials.gov
- Dec 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jan 2028 | Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease | |
| Phase 2/3Not yet recruiting | Dec 2028 | An Open-Label Study to Determine if BHV-1300 is Safe in Adults With Graves' Disease | |
| Phase 1Recruiting | Sep 2027 | Study of BHV-1300 in Graves' Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026